Dallas, TX -- (SBWIRE) -- 03/12/2015 -- The report "Acute Spinal Cord Injury – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Acute Spinal Cord Injury. Spinal cord injury damage to any part of the spinal cord or nerves at the end of the spinal canal often causes permanent changes in strength, sensation and other body functions below the site of the injury. Most injuries to the spinal cord don't completely sever it. An injury is more likely to cause fractures and compression of the vertebrae, which then crush and destroy the spinal nerve tracts. Complete report is available at http://www.rnrmarketresearch.com/acute-spinal-cord-injury-pipeline-review-h1-2015-market-report.html.

This report is complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Spinal Cord Injury and special features on late-stage and discontinued projects.

Companies discussed in this report include:
- Acorda Therapeutics, Inc.
- Kringle Pharma, Inc.
- Neuralstem, Inc.
- Neuronax SAS

Drugs profiled discussed in this report include AC-105, BA-210, Cell Therapy for Spinal Cord Injury, KP-100IT, NSI-566, NX-210, Peptide to Inhibit Ephrin-A for ALS and Acute Spinal Cord Injury, Peptides to Inhibit Major Histocompatibility Complex Class I and II for Central Nervous System and Musculoskeletal Disorders, Stem Cell Therapy for Acute Spinal Cord Injury. Order a copy of this report at (Prices start at US $ 2000 for a single user PDF) http://www.rnrmarketresearch.com/contacts/purchase?rname=310150.

Featured News & Press Releases:
- Nov 26, 2013: NX210 receives Orphan Drug Designation in Europe for the treatment of spinal cord injuries
- Jan 24, 2013: Acorda Therapeutics Announces Department Of Defense Contract To Support Study Of AC105 In Acute Spinal Cord Injury
- Oct 15, 2012: Neuronax receives 600.000 euros from Oseo to support its NX210 Project

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

List of Tables
Number of Products under Development for Acute Spinal Cord Injury, H1 2015 7
Number of Products under Development for Acute Spinal Cord Injury - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Products under Development by Companies, H1 2015 13
Products under Investigation by Universities/Institutes, H1 2015 14
Acute Spinal Cord Injury - Pipeline by Acorda Therapeutics, Inc., H1 2015 15
Acute Spinal Cord Injury - Pipeline by Kringle Pharma, Inc., H1 2015 16
Acute Spinal Cord Injury - Pipeline by Neuralstem, Inc., H1 2015 17
Acute Spinal Cord Injury - Pipeline by Neuronax SAS, H1 2015 18
Assessment by Monotherapy Products, H1 2015 19
Number of Products by Stage and Target, H1 2015 21
Number of Products by Stage and Mechanism of Action, H1 2015 23
Number of Products by Stage and Route of Administration, H1 2015 25
Number of Products by Stage and Molecule Type, H1 2015 27
Acute Spinal Cord Injury Therapeutics - Recent Pipeline Updates, H1 2015 41
Acute Spinal Cord Injury - Dormant Projects, H1 2015 49

Explore more reports on Central Nervous System (CNS) therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics.